Literature DB >> 20978319

VHL genetic alteration in CCRCC does not determine de-regulation of HIF, CAIX, hnRNP A2/B1 and osteopontin.

Michelle J Nyhan1, Shereen M El Mashad, Tracey R O'Donovan, Sarfraz Ahmad, Chris Collins, Paul Sweeney, Eamonn Rogers, Gerald C O'Sullivan, Sharon L McKenna.   

Abstract

BACKGROUND: von Hippel-Lindau (VHL) tumour suppressor gene inactivation is associated with clear cell renal cell carcinoma (CCRCC) development. The VHL protein (pVHL) has been proposed to regulate the expression of several proteins including Hypoxia Inducible Factor-α (HIF-α), carbonic anhydrase (CA)IX, heterogeneous nuclear ribonucleoprotein (hnRNP) A2/B1 and osteopontin. pVHL has been characterized in vitro, however, clinical studies are limited. We evaluated the impact of VHL genetic alterations on the expression of several pVHL protein targets in paired normal and tumor tissue.
METHODS: The VHL gene was sequenced in 23 CCRCC patients and VHL transcript levels were evaluated by real-time RT-PCR. Expression of pVHL's protein targets were determined by Western blotting in 17 paired patient samples.
RESULTS: VHL genetic alterations were identified in 43.5% (10/23) of CCRCCs. HIF-1α, HIF-2α and CAIX were up-regulated in 88.2% (15/17), 100% (17/17) and 88.2% (15/17) of tumors respectively and their expression is independent of VHL status. hnRNP A2/B1 and osteopontin expression was variable in CCRCCs and had no association with VHL genetic status.
CONCLUSION: As expression of these proposed pVHL targets can be achieved independently of VHL mutation (and possibly by hypoxia alone), these data suggests that other pVHL targets may be more crucial in renal carcinogenesis.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20978319      PMCID: PMC4605534          DOI: 10.3233/ACP-CLO-2010-0541

Source DB:  PubMed          Journal:  Anal Cell Pathol (Amst)        ISSN: 2210-7177            Impact factor:   2.916


  6 in total

1.  Tubulocystic renal cell carcinoma: is there a rational reason for targeted therapy using angiogenic inhibition? Analysis of seven cases.

Authors:  Petr Steiner; Milan Hora; Jan Stehlik; Petr Martinek; Tomas Vanecek; Fredrik Petersson; Michal Michal; Marie Korabecna; Ivan Travnicek; Ondrej Hes
Journal:  Virchows Arch       Date:  2013-01-08       Impact factor: 4.064

2.  Constitutive expression of HIF-α plays a major role in generation of clear-cell phenotype in human primary and metastatic renal carcinoma.

Authors:  Károly Tóth; Sreenivasulu Chintala; Youcef M Rustum
Journal:  Appl Immunohistochem Mol Morphol       Date:  2014-10

3.  Prolyl hydroxylase 2 dependent and Von-Hippel-Lindau independent degradation of Hypoxia-inducible factor 1 and 2 alpha by selenium in clear cell renal cell carcinoma leads to tumor growth inhibition.

Authors:  Sreenivasulu Chintala; Tanbir Najrana; Karoly Toth; Shousong Cao; Farukh A Durrani; Roberto Pili; Youcef M Rustum
Journal:  BMC Cancer       Date:  2012-07-17       Impact factor: 4.430

4.  Transforming growth factor-β promotes aggressiveness and invasion of clear cell renal cell carcinoma.

Authors:  Raviprakash T Sitaram; Pramod Mallikarjuna; Maréne Landström; Börje Ljungberg
Journal:  Oncotarget       Date:  2016-06-14

5.  VHL Dependent Expression of REDD1 and PDK3 Proteins in Clear-cell Renal Cell Carcinoma.

Authors:  Bojana B Ilic; Jadranka A Antic; Jovana Z Bankovic; Ivana T Milicevic; Gordana S Rodic; Dusan S Ilic; Cane D Tulic; Vera N Todorovic; Svetozar S Damjanovic
Journal:  J Med Biochem       Date:  2018-01-01       Impact factor: 3.402

6.  TGF-β inducible epithelial-to-mesenchymal transition in renal cell carcinoma.

Authors:  Sandy Tretbar; Peter Krausbeck; Anja Müller; Michael Friedrich; Christoforos Vaxevanis; Juergen Bukur; Simon Jasinski-Bergner; Barbara Seliger
Journal:  Oncotarget       Date:  2019-02-19
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.